Pfizer, BMS' Eliquis tops list of drugs destined for Medicare price negotiations in 2026

Pfizer, BMS' Eliquis tops list of drugs destined for Medicare price negotiations in 2026

Source: 
Fierce Pharma
snippet: 

Drug price negotiation is the boogeyman awaiting Big Pharma in 2026. So, which medicines will be subject to the U.S. government’s newfound ability to broker prices—the most impactful measure from last year’s Inflation Reduction Act?